Image
Point-of-Care 201

New Paths to Managing Anemia Associated with Chronic Kidney Disease

Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease.

Kidney Int Suppl. 2012;2(4):279-335. 

Drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease.

US Food and Drug Administration. Updated August 4, 2017. Accessed November 21, 2019.

Patient Resources

Informational resources for patients who have anemia and chronic kidney disease

Anemia and chronic kidney disease.

National Kidney Foundation

Anemia in chronic kidney disease.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Resource for people who want to learn more about clinical trials

NIH clinical research trials and you. 

National Institutes of Health

Suggested Readings

Anemia, diabetes, and chronic kidney disease. 

Mehdi U, Toto RD. Diabetes Care. 2009;32(7):1320-1326. 

Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature.

van Nooten FE, Green J, Brown R, Finkelstein FO, Wish J. J Med Econ. 2010;13(2):241-256.

Prevalence of anemia in chronic kidney disease in the United States.

Stauffer ME, Fan T. PloS One. 2014;9(1):e84943.

Pathophysiology of renal anaemia.

Geddes CC. Nephrol Dial Transplant. 2019;34(6):921-922. 

Intravenous iron in patients undergoing  maintenance hemodialysis

Macdougall IC, White C, Anker SD, et al; for the PIVOTAL Investigators and Committees. [published correction appears in N Engl J Med. 2019;380(5):502]. N Engl J Med. 2019;380(5):447-458. 

Roxadustat for anemia in patients with kidney disease not receiving dialysis.

Chen N, Hao C, Peng X, et al. N Engl J Med. 2019;381(11):1001-1010. 

Roxadustat treatment for anemia in patients undergoing long-term dialysis.

Chen N, Hao C, Liu B-C. N Engl J Med. 2019;381(11):1011-1022. 

OLYMPUS: A phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent CKD and anemia.

Fishbane S, et al. ASN Kidney Week; November 6-10, 2019; Washington, DC: Abstract TH-OR023. 

ROCKIES: An international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients.

Fishbane S, et al. ASN Kidney Week; November 6-10, 2019; Washington, DC: Abstract TH-OR022. 

HIMALAYAS: A phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients.

Provenzano R, et al. ASN Kidney Week; November 6-10, 2019; Washington, DC: Abstract TH-OR121. 

Pooled efficacy and CV analyses of roxadustat in the treatment of anemia in CKD patients on and not on dialysis.

Provenzano R, et al. ASN Kidney Week; November 6-10, 2019; Washington, DC, Abstract FR-OR131. 

A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.

Bailey CK, Caltabiano S, Cobitz AR, Huang C, Mahar KM, Patel VV. BMC Nephrol. 2019;20(1):372.

Mechanisms of hypoxia signalling: new implications for nephrology.

Schödel J, Ratcliffe PJ. Nat Rev Nephrol. 2019;15(10):641-659.

Hypoxia-inducible factor activators in renal anemia: current clinical experience.

Sanghani NS, Haase VH. Adv Chronic Kidney Dis. 2019;26(4):253-266.

Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. 

Yamamoto H, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Akizawa T. BMJ Open. 2019;9(6):e026704.

Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. 

Akizawa T, Macdougall IC, Berns JS, et al. Nephron. 2019;143:243-254. 

Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors to treat anemia in chronic kidney disease. 

Sakashita M, Tanaka T, Nangaku M. Contrib Nephrol. 2019;198:112-123. 

Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.

McMahon GM, Singh AK. Curr Opin Nephrol Hypertens. 2019;28(6):600-606. 

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Pfeffer MA, Burdmann EA, Chen C-Y, et al; for the TREAT Investigators. N Engl J Med. 2009;361(21):2019-2032. 

Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.

McCullough PA, Barnhart HX, Inrig JK, et al. Am J Nephrol. 2013;37(6):549-558. 

Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.

Inrig JK, Barnhart HX, Reddan D, et al. Am J Kidney Dis. 2012;60(3):390-401.

Anemia in conventional hemodialysis: finding the optimal treatment balance.

Hasegawa T, Koiwa F, Akizawa T. Semin Dial. 2018;31(6):599-606.

Anemia and cardiovascular risk: the lesson of the CREATE trial.

Locatelli F, Del Vecchio L, Pozzoni P. J Am Soc Nephrol. 2006;17(12 suppl 3):S262-S266.

Interactive Presentation

Clinical Insights Into Chronic Kidney Disease


Activity
New Paths to Managing Anemia Associated With Chronic Kidney Disease

A Guide to Healthcare Advances for Specialist Clinicians

Relevant Resources

Incretin-Based Therapies for Type 2 Diabetes

Mechanism-Based Strategies to Achieve Patient-Centered Care

Insulin Replacement Therapy for Type 2 Diabetes

Patient-Centered Management of Hyperglycemia in Primary Care

Improving Outcomes in Type 2 Diabetes

Integrating GLP-1 Receptor Agonists Into Multimodal Treatment Regimens

A Focus on Bipolar Depression

Overcoming Diagnostic Barriers and Optimizing Long-Term Patient Outcomes

Acute Management of Migraine Attacks

Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Clinical Issues in Type 2 Diabetes

Discussions and Debates Around GLP-1 Receptor Agonists

Clinical Issues in Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Opioid-Induced Constipation

Proactive Diagnosis and Targeted Management

Chronic Obstructive Pulmonary Disease, Asthma, or Both

Differential Diagnosis and Comprehensive Management Strategies

Improving Outcomes for Women with Type 2 Diabetes

Individualizing Evidence-Based Care

Improving Outcomes in Chronic Obstructive Pulmonary Disease

Optimizing Maintenance Therapy Across Healthcare Settings

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Clinical Issues in Chronic Pain

Consensus and Controversies for Responsible Opioid Prescribing

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Congenital and Acquired Lipodystrophy

Best Practices in Diagnosis and Management

Clearing the Air

Improving Outcomes for Patients with COPD

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

Clinical Issues in Type 2 Diabetes

Consensus and Controversies Around Intensifying Noninsulin Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Improving Outcomes in Non–24-Hour Sleep-Wake Disorder

Identifying Patients and Tailoring Therapy

Comprehensive Management of Chronic Obstructive Pulmonary Disease

Collaborative Approaches to Guideline-Concordant Patient Care

Clinical Updates in the Management of Severe Asthma

New Strategies for Individualizing Long-term Care

Comprehensive Chronic Pain Management

A Focus on Patients With Opioid-Induced Constipation

Clinical Issues in Bipolar Depression

Consensus and Controversies Across the Spectrum of Patient Presentations

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Caring for Patients with Severe Asthma

Evolving Best Practices to Optimize Outcomes

Can You Spot Axial Spondyloarthritis?

The PCP’s Role in Timely Recognition and Referral

Clinical Updates in Type 2 Diabetes

An Evolving Role for Combinations of Injectable Antihyperglycemic Therapies

Raising the Bar by Lowering the Target

Integrating PCSK9 Inhibitors Into Hypercholesterolemia Management

Injecting New Ideas into Managing Type 2 Diabetes

Evolving Roles of GLP-1 Receptor Agonists

Advancing the Care of Severe Asthma

Differential Diagnosis, Multidisciplinary Management, and Patient Engagement

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Multidimensional Issues in Type 2 Diabetes

Looking Beyond Hemoglobin A1c

Clearing the Air in Severe Asthma Management

Improving Patient Outcomes Through Shared Clinical Decision Making

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Pharmaceutical Economics and LDL-C Management

Implications for PCSK9 Inhibitors in Clinical Practice

Airing It Out

A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis

COPD in Managed Care

The Clinical and Utilization Benefits of Exacerbation Prevention

Assimilating the Evidence in T2DM

Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

Demystifying New Evidence for COPD Management

Best Practices for Primary Care

Finding Relief in Osteoarthritis

New Paths to Chronic Pain Management

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP